GLP-1 Pricing Data & Open Datasets

Telehealth Pricing Index

• 01

  Compounded semaglutide ranges from $86 to $348/month across US telehealth providers — a nearly 4x price spread for the same molecule

• 02

  Ozari Health's $86/month starter plan is the lowest all-in verified price among LegitScript-certified, all-50-state providers with a named pharmacy and no membership fee

• 03

  Several major platforms advertise low medication prices but add mandatory $79–$149/month membership fees, materially increasing the true monthly cost

• 04

  Brand-name Wegovy retails at ~$1,349/month without insurance — compounded semaglutide can represent up to $15,000/year in patient savings

• 05

  Only a minority of GLP-1 telehealth providers publicly name their compounding pharmacy partner, limiting supply-chain transparency

Clinical Trials Index

• 01

  Tirzepatide produced the largest mean weight loss in head-to-head Phase 3 data, with SURMOUNT-1 reporting ~20.9% mean reduction at 72 weeks vs ~14.9% for semaglutide 2.4 mg in STEP 1

• 02

  Across STEP 1–8, ≥5% weight-loss responder rates for semaglutide 2.4 mg consistently exceeded 80%, with ≥15% responder rates above 50% in most trials

• 03

  SELECT showed a 20% relative reduction in major adverse cardiovascular events for semaglutide 2.4 mg in adults with overweight/obesity and established cardiovascular disease without diabetes

• 04

  FLOW demonstrated a 24% relative reduction in major kidney disease events with semaglutide 1.0 mg in type 2 diabetes and chronic kidney disease

• 05

  Oral semaglutide (OASIS 1) and orforglipron (ATTAIN) extend GLP-1 weight-loss efficacy into oral formulations, with mean reductions of ~15% and ~12% respectively

Side Effects Frequency Database

• 01

  Nausea is the most common GLP-1 adverse event, reported in roughly 40–55% of patients on semaglutide and tirzepatide at therapeutic doses versus ~10–20% on placebo

• 02

  Most gastrointestinal side effects emerge during dose escalation in the first 4–12 weeks and are mild-to-moderate and transient in the majority of patients

• 03

  Treatment discontinuation due to adverse events in Phase 3 GLP-1 trials typically ranges 4–7%, only modestly above placebo (~2–3%)

• 04

  Tirzepatide and semaglutide show broadly similar adverse event profiles

• 05

  Oral semaglutide and orforglipron carry comparable GI tolerability profiles to injectable GLP-1s

Telehealth Pricing Index

@dataset{ozarihealth2026pricing,
  author    = {Ozari Health},
  title     = {GLP-1 Weight Loss Telehealth Pricing Index — United States, 2026},
  year      = {2026},
  license   = {CC-BY-4.0},
  url       = {https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026}
}

Clinical Trials Index

@dataset{ozarihealth2026trials,
  author    = {Ozari Health},
  title     = {GLP-1 Clinical Trials Index 2026},
  year      = {2026},
  license   = {CC-BY-4.0},
  url       = {https://huggingface.co/datasets/Ozarihealth/glp1-clinical-trials-2026}
}

Side Effects Frequency Database

@dataset{ozarihealth2026sideeffects,
  author    = {Ozari Health},
  title     = {GLP-1 Side Effects Frequency Database 2026},
  year      = {2026},
  license   = {CC-BY-4.0},
  url       = {https://huggingface.co/datasets/Ozarihealth/glp1-side-effects-2026}
}